Lantheus (NASDAQ:LNTH) Stock Rating Reaffirmed as "Neutral" by Mizuho

Key Points

• Mizuho reaffirmed its “Neutral” rating on Lantheus but lowered its price target to $109 from $115, implying approximately 8.9% upside from the current price.
• Analyst sentiment is broadly cautious: Lantheus has a consensus “Hold” rating, with three Buy ratings and eleven Holds, and an average price target of $107.44.
• Lantheus recently exceeded quarterly expectations, reporting $1.55 in earnings per share versus a $1.30 estimate and revenue of $388.18 million versus $363.23 million expected.

Lantheus (NASDAQ:LNTH - Get Free Report)'s stock had its "neutral" rating reissued by analysts at Mizuho in a research report issued on Tuesday, Benzinga reports. They currently have a $109.00 target price on the medical equipment provider's stock, down from their previous target price of $115.00. Mizuho's target price would suggest a potential upside of 8.88% from the stock's current price.

A number of other brokerages also recently issued reports on LNTH. TD Cowen downgraded Lantheus from a "buy" rating to a "hold" rating and lowered their price target for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. Leerink Partners set a $102.50 target price on shares of Lantheus in a report on Monday, August 3rd. B. Riley Financial cut shares of Lantheus from a "buy" rating to a "hold" rating in a research note on Monday, August 17th. William Blair set a $102.50 price target on shares of Lantheus in a research note on Monday, August 3rd. Finally, CJS Securities downgraded shares of Lantheus from a "market outperform" rating to a "market perform" rating in a report on Tuesday, August 4th. Three research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $107.44.

Lantheus Stock Down 0.0%

Shares of NASDAQ:LNTH opened at $100.11 on Tuesday. The company has a market cap of $6.53 billion, a price-to-earnings ratio of 24.18 and a beta of -0.06. Lantheus has a 12 month low of $50.15 and a 12 month high of $111.86. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average price of $100.47 and a 200 day moving average price of $97.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.30 by $0.25. The company had revenue of $388.18 million for the quarter, compared to analysts' expectations of $363.23 million. Lantheus had a return on equity of 28.10% and a net margin of 17.69%. The firm's revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.57 earnings per share. As a group, equities research analysts predict that Lantheus will post 4.54 earnings per share for the current year.

Institutional Trading of Lantheus

A number of large investors have recently made changes to their positions in LNTH. Western Wealth Management LLC purchased a new stake in Lantheus in the 1st quarter valued at about $25,000. Bessemer Group Inc. grew its stake in Lantheus by 221.2% in the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider's stock worth $39,000 after acquiring an additional 354 shares in the last quarter. Allworth Financial LP bought a new position in Lantheus in the 2nd quarter worth about $49,000. Farther Finance Advisors LLC increased its position in shares of Lantheus by 122.9% during the third quarter. Farther Finance Advisors LLC now owns 555 shares of the medical equipment provider's stock worth $55,000 after acquiring an additional 306 shares during the period. Finally, Versant Capital Management Inc increased its position in shares of Lantheus by 33.0% during the second quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider's stock worth $65,000 after acquiring an additional 146 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc NASDAQ: LNTH is a healthcare company that develops, manufactures and commercializes diagnostic and therapeutic products, with a focus on medical imaging and radiopharmaceuticals. Its products are used by physicians and healthcare providers to help detect, characterize and monitor disease.

The company's portfolio includes PYLARIFY (piflufolastat F 18), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in men with prostate cancer, and DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound imaging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.